Furthermore, the Mmp14 Y573D/Y573D mouse phenotypes are rescued by wild-type BM transplant. These results provide the first in vivo demonstration that MT1-MMP, an ECMdegrading proteinase, modulates bone, cartilage and fat homeostasis through a proteolysis-independent, intracellular signaling mechanism that controls SSC differentiation.
INTRODUCTION
Membrane-type 1 matrix metalloproteinase (MT1-MMP, or , the product of the gene MMP14, is a cell-membrane-bound proteinase with an extracellular catalytic site and a 20-amino acid cytoplasmic tail 1, 2 . It degrades a variety of ECM components and is expressed by a wide array of normal and tumor cells. Notably, MT1-MMP is the only MMP whose genetic deficiency in the mouse results in severe phenotypes and early death.
These features have implicated MT1-MMP as an important component of the proteolytic mechanisms of physiological and pathological processes including bone, cartilage and adipose tissue homeostasis, as well as tumor invasion, angiogenesis and metastasis.
The analysis of the phenotype of mice genetically deficient in MT1-MMP (Mmp14 -/-) has shown key roles of this proteinase in the postnatal development and growth of cartilage, bone and adipose tissue. Mmp14 deficiency in the mouse results in dwarfism, severe osteopenia, generalized arthritis and lipodystrophy, among other abnormalities [3] [4] [5] [6] . In humans a mutation of MMP14 causes multicentric osteolysis and arthritis disease, or Winchester syndrome, which recapitulates much of the phenotype of the Mmp14 -/-mouse 7 . Conditional Mmp14 knockout in uncommitted skeletal stem cells (SSC, also referred to as mesenchymal stem cells), the common progenitors of osteoblasts, chondrocytes and adipocytes, recapitulates the skeletal phenotype of the global Mmp14 knockout mouse 8 .
Conversely, unlike global Mmp14 deficiency conditional Mmp14 knockout in SSC results
in thickening of articular cartilage and increased bone marrow (BM)-associated fat but decreased subcutaneous fat, which derives from distinct progenitor cells 5, 9, 10 . In light of the fundamental role of MT1-MMP in ECM degradation, it has been proposed that the phenotypes of Mmp14 -/-mice result from defective collagen turnover [3] [4] [5] [6] . 4 However, a number of in vitro studies have provided evidence for a variety of nonproteolytic roles of MT1-MMP. We have previously shown that the MT1-MMP cytoplasmic tail activates Ras-ERK1/2 and AKT signaling by a non-proteolytic mechanism that controls cell proliferation, migration and apoptosis in vitro, as well as tumor growth in vivo 11, 12 . Signaling is activated in a dose-and time-dependent manner by MT1-MMP binding of low nanomolar concentrations of tissue inhibitor of metalloproteinases-2 (TIMP-2), a physiological protein inhibitor of MT1-MMP. Signaling activation is also mediated by mutant TIMP-2 lacking MMP inhibitory activity (Ala+ TIMP-2) as well as by mutant MT1-MMP devoid of proteolytic activity (MT1-MMP E240A), showing that the signaling mechanism is proteolysis-independent. We also showed that MT1-MMP signaling requires the unique tyrosine (Y573) in the cytoplasmic tail, which is phosphorylated by Src and LIM1 kinases 13, 14 , and that Y573 substitution with aspartic acid (Y573D), a negatively charged amino acid like phosphotyrosine, abrogates MT1-MMP-mediated activation of Ras-ERK1/2 11 . Other groups have subsequently found that Y573 controls a variety of signaling pathways and cell functions in vitro [15] [16] [17] [18] [19] [20] . Y573 is required for activation of the small GTPase Rac1 11, 20 , controls macrophage migration and infiltration at sites of inflammation 19, 20 , as well as MT1-MMP interaction with Src and focal adhesion kinase (FAK) 21 .
Based on these observations, we generated a mutant mouse with the Y573D substitution in the cytoplasmic tail of MT1-MMP (MT1-MMP Y573D). Here we report that this mouse shows abnormalities in postnatal bone, cartilage and adipose tissue development and growth that partly recapitulate the phenotype of the MMP14 -/-mouse.
These phenotypes derive from dysregulation of BM SSC differentiation, and are rescued by wild-type (wt) BM transplant. 5 
RESULTS

Generation and characterization of MT1-MMP Y573D mice
Mice heterozygous (Mmp Y573D/wt ) or homozygous (Mmp Y573D/Y573D ) for the MT1-MMP Y573D mutation, generated as described in Experimental procedures (Fig. S1 ), were macroscopically indistinguishable from Mmp14 wt/wt mice at birth. However, after the first 2 months Mmp14 Y573D/wt and Mmp14 Y573D/Y573D mice showed a slightly lower growth rate than their Mmp14 wt/wt littermates. In mice older than 3 months the weight of Mmp14 Y573D/Y573D male and female mice was 15 % lower than that of age-and sex- By Western blotting (Fig. S2 C) , Mmp14 Y573D/Y573D mice showed tissue levels of MT1-MMP comparable to that of Mmp14 wt/wt mice. Consistent with previous findings 22 , primary fibroblasts from 3-weeks old Mmp14 Y573D/Y573D mice and Mmp14 wt/wt littermates had similar MT1-MMP proteolytic activity. Similarly, flow cytometry of peripheral blood leukocytes from Mmp14 Y573D/Y573D and Mmp14 wt/wt mice showed comparable levels of cell surface-associated MT1-MMP (Fig. 2S D and E) . Thus, the Y573D mutation did not significantly alter the plasma membrane expression or proteolytic activity of MT1-MMP.
In addition, in agreement with our previous findings 11 , primary fibroblasts from Mmp14 Y573D/Y573D mice showed strongly reduced ERK1/2 and AKT activation in response to exogenous TIMP-2 relative to Mmp14 wt/wt cells (Fig. S2 F (Figs. 1 B -D) . This effect was accompanied by increased TRAP-positive osteoclasts, indicating enhanced bone remodeling (Fig. S3) , a feature also observed in Mmp14 -/-mice [4] .
Gene expression profiling of bone from Mmp14 Y573D/Y573D mice ( Fig. 1 E) showed that 76 genes were significantly up-or downregulated relative to Mmp14 wt/wt littermates (p ≤ 0.05). Consistent with the morphometric analyses, gene ontology analysis showed highly significant enrichment for biological processes related to osteoblast differentiation, bone remodeling, ossification and bone growth (Fig. 1 F) .
The knee joints of 2-month old mice showed several abnormalities. Both Mmp14 Y573D/wt and Mmp14 Y573D/Y573D mice displayed marked thinning of articular cartilage ( Fig. 2 A top panels, and B) with loss of proteoglycans ( Fig. 2 C and D) , clustering and cloning of chondrocytes ( Fig. 2 A lower panels) , classic histologic features of the articular 7 cartilage degeneration associated with human osteoarthritis (OA) and surgical models of OA in mice. The knee cartilage of 2-year old mice also showed fissures, chondrocyte clustering and cloning, abnormalities typical of ageing-associated degeneration that were not observed in age-and sex-matched Mmp14 wt/wt mice (Fig. 2 E) .
RNA seq analysis of the transcriptome of cartilage from Mmp14 Y573D/Y573D mice ( Fig.   3 A) showed significant dysregulation of the expression of 1,549 genes relative to Mmp14 wt/wt mice (p ≤ 0.05). Of these genes, 694 were upregulated 2-fold or more, and 92 were downregulated 50% or more. Gene ontology analysis (Fig. 3 B) showed highly significant enrichment for biological processes related to extracellular matrix homeostasis, cartilage development and chondrocyte differentiation. As these biological processes are strongly dysregulated in human OA, we analyzed the transcriptome of Mmp14 Y573D/Y573D cartilage for expression of genes involved in human OA (Fig. 3 C) . Gene expression profiling of human OA cartilage has revealed 1,423 genes significantly up-or downregulated (p ≤ 0.05) relative to normal cartilage, 111 of which are strongly up-or dowregulated (≥ 2-fold or ≤ 50%) 23, 24 . We found that 48 of these 111 OA-associated genes are also strongly regulated in Mmp14 Y573D/Y573D mouse cartilage, including all the genes for collagens and other ECM proteins upregulated in human OA, ECM-degrading proteinases, and genes involved in cell metabolism (Figure 3 D) . Thus, consistent with its histological features, Mmp14 Y573D/Y573D joint cartilage showed significant gene expression similarity with human OA.
Sections of the long bones of adult Mmp14 Y573D/wt and Mmp14 Y573D/Y573D mice also showed marked decrease in BM-associated fat relative to Mmp14 wt/wt littermates ( Moreover, similar to Mmp14 +/-mice, Mmp14 Y573D/Y573D mice were protected from body weight gain induced by high-fat diet (Fig. S7) .
In addition to reduced WAT, Mmp14 Y573D/Y573D mice showed strongly decreased fasting levels of plasma insulin relative to age and sex-matched Mmp14 wt/wt littermates (Fig. 6) , with normoglycemia and normal food consumption (Fig. S8) . Mmp14 Y573D/Y573D and Mmp14 wt/wt mice also had comparable levels of ACTH, which controls adipose tissue metabolism, and leptin, a hormone secreted predominantly by adipose tissue.
Conversely, Mmp14 Y573D/Y573D mice had extremely low serum levels of the inflammatory 9 cytokines interleukin-6 (IL-6), monocyte chemoattractant protein 1/ chemokine (C-C motif) ligand 2 (MCP-1/CCL2), and IL-10 relative to age-and sex-matched Mmp14 wt/wt mice (Fig. 6 ).
MT1-MMP Y573D expression alters skeletal stem cell proliferation and apoptosis, and skews differentiation from chondro-and adipogenesis towards osteogenesis
The observation that the phenotype of Mmp14 Y573D/Y573D mice involves abnormalities of bone, cartilage and adipose tissue indicated that the MT1-MMP Y573D mutation might affect the differentiation of SSC, the common progenitor cells of these tissues. Therefore, we isolated SSC from the BM of Mmp14 wt/wt and Mmp14 Y573D/Y573D littermates, and characterized them in vitro (Fig. 7) . Mmp14 Y573D/Y573D SSC contained fewer colonyforming units-fibroblasts (CFU-F) than Mmp14 wt/wt SSC (1.5x10 -6 vs. 4.5x10 -6 , respectively), formed much smaller colonies (Fig. 7 A) , and showed remarkably lower proliferation rate and higher apoptosis index ( Fig. 7 B and C We then characterized the trabecular and cortical bone of the femurs of the transplanted mice by microCT analysis (Fig. 8) . The results showed that transplantation of Mmp14 wt/wt BM had no effect on the cortical bone of Mmp14 Y573D/Y573D mice transplanted at 3 months ( [3 -6] 27 . The striking abnormalities of Mmp14 -/-mice -dwarfism, severe osteopenia, generalized arthritis, fibrosis and lipodystrophyhave been ascribed to impaired collagen turnover, which also plays a fundamental role in SSC differentiation and affects adipocyte development [3 -6] . The data presented in this paper show that, in addition to its proteolytic activity, MT1-MMP contributes to bone, cartilage and adipose tissue homeostasis through a proteolysis-independent mechanism mediated by its cytoplasmic domain. This conclusion is based on the following observations.
We have previously shown that MT1-MMP activates ERK1/2 and AKT signaling upon binding of physiological concentrations of TIMP-2 11,12 . Signaling is activated by mutant MT1-MMP devoid of proteolytic activity (MT1-MMP E240A) or TIMP-2 lacking MMP inhibitory activity (Ala+ TIMP-2), and is blocked by the Y573D substitution in the MT1-MMP cytoplasmic tail. As this mutation does not significantly alter the cell surface expression or proteolytic activity of MT1-MMP 22 (Fig. S2 ), these findings showed that MT1-MMP activation of ERK1/2 and AKT signaling is independent of its proteolytic activity and mediated by its cytoplasmic domain.
To investigate the physiological significance of our in vitro findings we generated a mouse in which MT1-MMP activation of ERK1/2 and AKT is abrogated by the Y573D mutation. The data presented in this paper show that mice bearing this mutation present phenotypes that recapitulate those caused by Mmp14 deficiency. The phenotypes of [29] [30] [31] , indicating that MT1-MMP expression must be strictly controlled for normal cartilage homeostasis. In Mmp14 Y573D/Y573D mice chondrocyte expression of MT1-MMP is lower than in Mmp14 wt/wt mice ( Fig. 7 F) ; however, their cartilage is thinner and presents signs of degeneration, showing that altering MT1-MMP signaling has a pathological effect even in the presence of low levels of MT1-MMP proteolytic activity. Thus, MT1-MMP signaling is required for articular cartilage homeostasis. mice show decreased adipocyte differentiation. MT1-MMP has been shown to be a fundamental effector of adipocyte growth through collagen degradation, a process required for adipocyte increase in size 5, 6 . This conclusion is based on the study of (Fig. 7 A -C) . We MT1-MMP is constitutively expressed in SSC and its levels are differentially modulated during osteogenic vs. chondrogenic/adipogenic differentiation 8 . The MT1-MMP Y573D mutation and Mmp14 deficiency have opposing effects on SSC differentiation in vitro. Mmp14 knockout in uncommitted SSC has no effect on their differentiation in 2D culture; however, it causes decreased osteogenesis and increased chondro-and adipogenesis in 3D collagen gel 8 . In contrast, in 2D culture MT1-MMP Y573D expression upregulates SSC differentiation into osteoblasts and downregulates chondrocyte and adipocyte differentiation (Fig. 7 F and G The relative contribution of proteolysis and signaling to MT1-MMP function is also coordinated by extracellular ligands that can inhibit extracellular MT1-MMP proteolytic activity and activate intracellular signaling. This hypothesis is supported by our previous finding that TIMP-2 binding to MT1-MMP activates ERK1/2 and Akt signaling [11, 12] , as well as by the observation that in the mouse embryo MT1-MMP is temporally and spatially co-expressed with TIMP-2 in the developing skeleton 34, 35 . TIMP-2 -/-mice do not display the severe phenotype of Mmp14 -/-mice 36 ; however, in these mice signaling can be activated by MT1-MMP binding of TIMP-3 or TIMP-4, as well as a variety of extracellular and transmembrane proteins, including integrins and CD44, that physiologically interact with the MT1-MMP ectodomains 37, 38 .
Thus, the loss of signaling function caused by the Y573D substitution 11, 12 (Fig. S2   F) can be at the basis of the defects in SSC differentiation and the consequent phenotypes of the Mmp14 Y573D/Y573D mouse. Studies by other groups, as well as our own (data not shown), have shown that, although ERK1/2 signaling is important for osteoblast differentiation [39] [40] [41] , chronic inhibition of ERK1/2 activation results in increased SSC 20 differentiation into osteoblasts [42] [43] [44] [45] [46] ; conversely, inhibition of PI3K/AKT signaling blocks adipo-and chondrogenesis [47] [48] [49] [50] .
The molecular mechanism that relays signaling from the Y573 residue of the MT1-MMP cytoplasmic tail to the Ras-ERK1/2 and Ras-AKT pathways 11, 12 , remains to be investigated. The adaptor protein p130Cas, which binds to the cytoplasmic tail of MT1-MMP by a mechanism involving Y573 [21] , recruits Src and/or focal adhesion kinase (FAK), which activate Ras 51, 52 . We speculate that TIMP-2 binding to MT1-MMP triggers the assembly of the p130Cas/Src/FAK complex at the MT1-MMP tail, and that this effect is abrogated by the Y573D substitution, which thus prevents the downstream activation of ERK1/2 and AKT signaling. In addition, Y573 could control intracellular signaling by modulating cytoplasmic tail interactions with a variety of transmembrane or membranebound proteins including caveolin-1 53-56 and ß1 integrins or growth factor receptors 57 .
In conclusion, our findings provide the first in vivo evidence for an important role of MT1-MMP mediated, proteolysis-independent signaling in postnatal development and tissue homeostasis. Understanding the relative contribution of the proteolytic and signaling functions of MT1-MMP to the control of metabolic processes that affect a variety of tissues and organs will require the development of additional genetically engineered mouse models, as well as the molecular dissection of extracellular and intracellular components of the MT1-MMP signaling mechanism. The knowledge obtained from these studies can increase our understanding of the pathogenesis of important diseases that affect bone, cartilage and adipose tissue homeostasis, such as osteopenia, osteoarthritis and obesity, and potentially direct the design of novel pharmacological tools for their treatment.
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MATERIALS AND METHODS
Generation of MT1-MMP Y573D mice
To generate a mouse with the Y573D mutation in the MT1-MMP cytoplasmic tail we constructed a targeting vector containing exons 2 to 10 of the genomic sequence of mouse MT1-MMP (Fig. S1 A) . A floxed neomycin resistance cassette was inserted into intron 9, adjacent to the 5' end of exon 10, which encodes Y573, and a hsv-thymidine kinase cassette was placed at the 5′ end of the construct. The TAC codon for Y573 was mutated into GAC by PCR. The construct was electroporated into W4 embryonic stem (ES) cells, followed by G418 and gancyclovir double selection. Homologous recombination targeting events were identified in 8 ES cell colonies. Two of these, devoid of chromosome abnormalities by cytogenetic analysis, were used for injection into blastocysts of C57BL/6 mice, and one gave germ-line transmission. Mice heterozygote for the mutation (Mmp14 Y573/wt ), identified by PCR analysis with primers flanking the neo cassette, were crossed with Rosa26Cre Deleter mice (C57BL/6NTac-Gt(ROSA)26Sor tm16(cre)Arte ; Taconic) to excise the neo cassette. Homozygote Mmp Y573D/Y573D mice were generated by heterozygote mating, and crossed back to wt C57BL/6 mice to remove the Cre recombinase gene. Sequencing of MT1-MMP cDNA from Mmp Y573D/Y573D mouse tissue showed identity with wt MT1-MMP except for the Y573D mutation. Heterozygote mating produced wt, heterozygote and homozygote mice in the expected mendelian ratios. The mice were genotyped by PCR using the same primers flanking the loxP sites, which afford identification of the three genotypes (Fig. S1 B). The sequences of these primers are: 
Micro-computed tomography (CT)
Micro-CT was performed according to published guidelines 58 . Bones were scanned using a high-resolution SkyScan micro-CT system (SkyScan 1172, Kontich, Belgium).
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Images were acquired using a 10 MP digital detector, 10W energy (70kV and 142 mA), and a 0.5-mm aluminum filter with a 9.7-μm image voxel size. A fixed global threshold method was used based on the manufacturer's recommendations and preliminary studies, which showed that mineral variation between groups was not high enough to warrant adaptive thresholds. The cortical region of interest was selected as the 2.0-mm mid-diaphyseal region directly below the third trochanter. The trabecular bone was assessed as the 2.0-mm region at the distal femur metaphysis, measurements included the bone volume relative to the total volume (BV/TV), bone mineral density (BMD), trabecular number (Tb.N), trabecular spacing (Tb.Sp), and trabecular thickness (Tb.Th).
Isolation, culture and differentiation of BM SSC
Cultures of BM SSC were established by a modification of the method described 59 .
BM was flushed from cut femurs and tibiae using 3-ml syringes with αMEM medium supplemented with 15% fetal calf serum (FBS) and antibiotics (Penicillin-Streptomycin, 10,000 U/mL). After separating the BM into a single-cell suspension, the cells were passed through a 70-μm cell strainer, incubated for 2 min in NH4Cl red blood cell lysis solution (StemCell Technologies, Vancouver, Canada), and seeded into culture plates in αMEM supplemented with 15% FBS and antibiotics. Three hours later non-adherent cells were removed by changing the medium and replacing with fresh complete medium. This procedure was repeated twice a day for the first 72 h. Subsequently, the adherent cells were washed with phosphate buffer saline (PBS) and incubated with fresh medium every 3-4 days until the cultures became subconfluent. To induce differentiation the cells were seeded into 24-well plates (5 x 10 4 cells/well). After 24 h, the culture medium was substituted with osteoblast or adipocyte differentiation medium, and incubation was 24 continued for the indicated times, with medium being changed with freshly prepared medium twice a week. For chondrocyte differentiation the cells were seeded into 48-well plates as a pellet (2.5 x 10 5 cells/well). The medium was substituted with freshly prepared differentiation medium 2 h after seeding, and subsequently three times a week.
Differentiation medium consisted of αMEM (DMEM) supplemented with 10% fetal bovine serum (FBS), antibiotics and, for osteoblast differentiation: dexamethasone 1 µM, betaglycerolphosphate 20 mM, L-ascorbic acid 50 µM; for adipocyte differentiation: dexamethasone 1 µM, indomethacin 50 µM, 3-Isobutyl-1-methylxanthine (IBMX) 500 nM, insulin 5 µg/ml; and for chondrocyte differentiation: sodium pyruvate 100 µg/ml, ascorbic acid 50 µg/ml, dexamethasone 0.1 µM, ITS mix (insulin, transferrin, selenium) 1X and bone morphogenetic protein-2 (BMP2) 300 ng/ml. SSC used for differentiation experiments were no older than passage 3 in culture. 
Quantitative PCR analysis of gene expression in differentiating cells
Cells were lysed in Trizol, and total RNA was isolated with RNeasy (Qiagen, Valencia, CA), according to the manufacturer's instructions. RNA was quantified using Nanodrop 2000 and 1 µg of total RNA was used for cDNA preparation using SuperScript III (Invitrogen, Life Technologies, CA). Quantitative real-time PCR reactions were performed with SYBR green PCR reagents using the ABI Prism 7300 sequence detection system (Life Technologies-Applied Biosystems). Relative gene expression levels were calculated using the 2 delta Ct method 60 . Target mRNA levels were normalized to the geomean of GAPDH and HPRT1 mRNA. The sequences of the primers used are shown in Supporting Material.
Analysis of circulating hormones and cytokines
Serum and/or plasma levels of the indicated hormones and cytokines were measured by multiplex ELISA kits (Millipore, Burlington, MA) at the High-Throughput Biology Laboratory of NYU School of Medicine.
RNA-sequencing and data analysis
Total RNA was extracted from the indicated tissues and SSC using the RNeasy kit (Qiagen, CA). RNA-seq libraries were prepared with the TruSeq sample preparation kit (Illumina, CA). Sequencing reads were mapped to the mouse genome using the STAR aligner (v2.5.0c) [51] . Alignments were guided by a Gene Transfer Format file (Ensembl GTF version GRCh37.70). The mean read insert sizes and their standard deviations were calculated using Picard tools (v.1.126). Read count tables were generated using HTSeq (v0.6.0) [52] , normalized to their library size factors with DESeq (v3.7) [53] , and differential expression analysis was performed. Read Per Million (RPM) normalized BigWig files 26 were generated using BEDTools (v2.17.0) [54] and bedGraphToBigWig tool (v4).
Statistical analyses were performed with R (v3.1.1), GO analysis with David Bioinformatics Resources 6.8 [55, 56] and GSEA with the hallmarks (h.all.v6.1.symbols.gmt) gene sets of the Molecular Signature Database (MSigDB) v6.1 [57, 58] .
BM transplant
Mice of 3 and 5 months of age were used for BM transplant experiments. The BM of female mice was transplanted into age-matched male mice. The recipient mice were lethally irradiated with a single dose of 9 Gy. Twenty-four hours later bone marrow cells (BMCs) were collected from the tibias and femurs of donor mice, suspended in PBS containing 2% heat-inactivated FBS, and 5 x 10 6 BMCs in 200 µl were injected into the recipient mice via the tail vein. Eight weeks later the mice were subjected to DEXA scanning analysis and then sacrificed. To verify BM engraftment we transplanted female mice with male BM, in order to characterize the recipients' BM by immunohistochemistry and/or flow cytometry with antibody to UTY, a Y chromosome marker 61 . However, several commercially available antibodies failed to recognize UTY in murine BM cells, probably because this marker is not expressed in these cells. For the same reasons we were not able to identify the genotype of transplanted animals' WAT or BAT by immunohistochemistry with UTY antibody, or RNA in situ hybridization. Therefore, we genotyped the BM of recipient mice for the Mmp14 Y573D/Y573D mutation using the PCR primers designed for genotyping our mice. We reasoned that partial engraftment of donor's BM would result in both the Mmp14 wt/wt and Mmp14 Y573D/Y573D genotypes, with a pattern of PCR products identical to that of Mmp14 Y573D/wt mice (Fig. S1 B) . In addition, 27 running the PCR reaction for a high number of cycles would afford detection of small residual amounts of BM from recipient mice. By this method, the results (Fig. S9) showed virtually complete replacement of the recipient's BM with the donors' BM. However, we could not use this method to identify donor-derived adipocytes in the transplanted animals' WAT or BAT as these tissues contain circulating cells -e.g. macrophages -from the BM.
Statistical analysis
Statistical analysis was performed with the two-tailed Student t test using GraphPad Prism, Version 7.05. The mice (n = 9-11/group) were transplanted at 3 months of age, and analyzed 2 months later. BV/TV: bone volume normalized to total tissue volume; Cs. Th.: cortical thickness; Ma. Ar.: bone marrow area. The YD►YD samples show~20% reduced cortical bone relative to wt ► wt samples, as expected ( Fig. 1 A) ; wt ► YD or YD► wt BM transplant does not change the phenotype of the recipient. Mean ± s.d. are shown. *: p = 0.0003; **: p = 0.0021; ‡: p = 0.0038. B. MicroCT 3D reconstruction (upper panels) and quantitative measurements (lower panels) of trabecular bone of the mice described in A. The YD►YD samples show 35-40% increase in trabecular bone relative to wt ► wt samples, as expected ( Fig. 1 B) ; Mmp14wt/wt BM transplant lowers the amount of trabecular bone in Mmp14 Y573D/Y573D mice to a level similar to that of the wt►wt controls (dotted line). Conversely, BM transplant from 
